{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23","upperLimit":"54.8","value":"38.9"},{"groupId":"OG001","lowerLimit":"48.6","upperLimit":"80.8","value":"64.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Overall response, Minimal Remission (MR) or better per treatment arm, using the uniform response criteria by the International Myeloma Working Group (IMWG) of pomalidomide in combination with high dose dexamethasone with or without cyclophosphamide in participants with relapsed and refractory myeloma. In addition, Minimal response was incorporated in those response criteria as this is a valid endpoint in patients with relapsed or refractory myeloma. MR: 25-49% reduction in serum paraprotein and a 50-89% reduction in urine light chain excretion; A 25-49% reduction in the size of soft tissue plasmacytoma must be demonstrated is applicable.","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase II: Pomalidomide and high dose dexamethasone.\n\nCrossover Arm D is a part of Arm B. Arm D was opened later to accommodate requested transfers from Arm B. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician.\n\nArm D participants may be referenced separately in some Outcome Measures.","id":"OG000","title":"B: Pomalidomide and Dexamethasone"},{"description":"Phase II: Pomalidomide high dose dexamethasone and oral cyclophosphamide.","id":"OG001","title":"C: Pomalidomide, Dexamethasone, Cyclophosphamide"}],"paramType":"NUMBER","populationDescription":"All Phase II Participants.","reportingStatus":"POSTED","timeFrame":"36 Months","title":"Phase II - Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}